Published • loading... • Updated
Diabetes and ADHD drugs to be tested on Alzheimer's patients in new study
The adaptive trial will test several repurposed medicines at once and could cut years from Alzheimer’s drug development, researchers said.
- The UK Dementia Research Institute and Alzheimer's Research UK launched the AD-SMART clinical trial, testing repurposed drugs atomoxetine and metformin to treat Alzheimer's disease affecting around 600,000 people in the UK.
- Chief Investigator Professor Paresh Malhotra stated that traditional Alzheimer's research has moved in a "grossly inefficient way," often taking four or five years to test one drug. The AD-SMART design allows simultaneous testing of multiple medications.
- The trial targets 1,200 people across more than 30 NHS sites, with first participant Angela Bucksey describing the study as empowering. Experts anticipate this adaptive approach could more than halve the time required to evaluate treatments compared to conventional methods.
- Prime Minister Andy Burnham, whose father Roy died with Alzheimer's in September, pledged support for the trial to prioritize dementia research. "I know how it feels to lose a loved one to dementia," Burnham said.
- Scientists expect to complete evaluations of the initial drugs by 2030, with plans to introduce additional therapies over the next 18 months. The approach applies advances from cancer research to accelerate testing through multiple mechanisms simultaneously.
Insights by Ground AI
16 Articles
16 Articles
Evening Standard+5 Reposted by 5 other sources
New clinical trial backed by Andy Burnham could speed up Alzheimer’s treatments
The Prime Minister’s father Roy died with Alzheimer’s disease in September.
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources16
Leaning Left4Leaning Right3Center6Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 31%
C 46%
R 23%
Factuality
To view factuality data please Upgrade to Premium
